Want to see CH:ALC full AI Analyst Report?
ALC Stock Chart & Stats
CHF63.90
-CHF2.00(-2.39%)
At close: 4:00 PM EST
CHF63.90
-CHF2.00(-2.39%)
Day’s Range― - ―
52-Week RangeCHF47.80 - CHF74.34
Previous CloseN/A
Volume235.38K
Average Volume (3M)1.47M
Market Cap
CHF27.08B
Enterprise ValueCHF31.95K
Total Cash (Recent Filing)CHF1.66B
Total Debt (Recent Filing)CHF5.25B
Price to Earnings (P/E)41.3
Beta1.05
Next Earnings
Aug 10, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume1,613,176
30 Day Avg. Volume1,472,733
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF70.11Price Target Upside9.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)2.74
Revenue Forecast (FY)CHF8.79B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetAlcon’s low leverage and sizeable equity base provide durable financial flexibility to invest in R&D, fund product rollouts and execute the $1.5B buyback without materially increasing financial risk. This balance-sheet strength supports multi-year strategy execution and resilience through cyclic procedure volumes.
Installed Base & Recurring ConsumablesEquipment placements (Unity and platform extensions) expand an installed base that drives recurring consumables and accessories. That installed-base-driven revenue mix creates durable, repeatable demand tied to procedure volumes and supports margin stability and predictable aftermarket cash flows over multiple years.
Consistent Product Innovation & Share GainsRapid adoption and measurable share gains for new launches (IOLs, Tryptyr, Unity extensions) show sustainable commercial traction. High refill rates and expanding coverage indicate durable demand and the potential for premiumization, supporting revenue mix improvement and long-term competitive positioning.
Bears Say
Recent Profitability & FCF WeaknessA meaningful TTM decline in net margin and free cash flow undermines internal funding capacity and raises execution risk for planned investments. If earnings quality and cash conversion don’t recover, Alcon may face pressure on organic investment pace and capital return without altering leverage.
Tariff & Supply-Chain Margin PressureMaterial tariff exposure and episodic supply disruptions directly compress gross margins and increase cost volatility. Such structural trade-policy and logistics risks can persist across quarters, forcing higher prices, margin dilution or sustained investment to re-shore/mitigate supply chain, which weighs on durable margin sustainability.
Geographic & Procedure-Volume ExposureAlcon’s growth depends on procedure volumes and geographic recovery. Protracted China weakness and softer cataract activity, alongside increasing implantable competition, can limit implantables and consumables growth. This concentration risk could mute durable revenue expansion absent broad-based volume recovery or share gains.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was CHF47.80 and its highest was CHF74.34 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is CHF27.08B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 25 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported CHF0.662 earnings per share for the quarter, beating the consensus estimate of CHF0.636 by CHF0.026.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of CHF0.28 which represents an annual dividend yield of 0.44%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.6.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of CHF0.662 in its last earnings report, beating expectations of CHF0.636. Following the earnings report the stock price went down -10.958%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in CH:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF70.11 (9.71% Upside)
CHF70.11 (9.71% Upside)
Blogger Sentiment
Bullish
CH:ALC Sentiment 70%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.06%
12-Months-Change
Fundamentals
Return on Equity
3.69%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Stock 12 Month Forecast
Average Price Target
CHF70.11
▲(9.71% Upside)